Cooperating, congenital neutropenia–associated Csf3r and Runx1 mutations activate pro-inflammatory signaling and inhibit myeloid differentiation of mouse HSPCs
Male
0301 basic medicine
Neutropenia
Mice, Transgenic
Colony-Forming Units Assay
Mice
03 medical and health sciences
Receptors, Colony-Stimulating Factor
Animals
Congenital Bone Marrow Failure Syndromes
Preleukemia
Myeloid Cells
RNA, Messenger
Inflammation
Myelopoiesis
Gene Expression Profiling
Hematopoietic Stem Cells
Immunity, Innate
Recombinant Proteins
3. Good health
Mice, Inbred C57BL
Core Binding Factor Alpha 2 Subunit
Original Article
Specific Pathogen-Free Organisms [MeSH] ; RNA, Messenger/biosynthesis [MeSH] ; Mice, Inbred C57BL [MeSH] ; Receptors, Colony-Stimulating Factor/genetics [MeSH] ; Colony-Forming Units Assay [MeSH] ; Myeloid Cells/pathology [MeSH] ; Inflammation [MeSH] ; Preleukemia/genetics [MeSH] ; Core Binding Factor Alpha 2 Subunit/genetics [MeSH] ; RNA, Messenger/genetics [MeSH] ; Cell Division [MeSH] ; Original Article ; Mice, Transgenic [MeSH] ; Male [MeSH] ; Core Binding Factor Alpha 2 Subunit/physiology [MeSH] ; Severe congenital neutropenia ; Recombinant Proteins/genetics [MeSH] ; Immunity, Innate [MeSH] ; Neutropenia/congenital [MeSH] ; Preleukemia/pathology [MeSH] ; RUNX1 mutations ; Congenital Bone Marrow Failure Syndromes/genetics [MeSH] ; Neutropenia/genetics [MeSH] ; Congenital Bone Marrow Failure Syndromes/pathology [MeSH] ; Animals [MeSH] ; Receptors, Colony-Stimulating Factor/physiology [MeSH] ; Mice [MeSH] ; Hematopoietic Stem Cells/pathology [MeSH] ; Pre-leukemia bone marrow failure syndrome ; Neutropenia/pathology [MeSH] ; Gene Expression Profiling [MeSH] ; Myelopoiesis/genetics [MeSH] ; G-CSFR mutations
Cell Division
DOI:
10.1007/s00277-020-04194-0
Publication Date:
2020-08-31T13:20:08Z
AUTHORS (10)
ABSTRACT
AbstractPatients with the pre-leukemia bone marrow failure syndrome called severe congenital neutropenia (CN) have an approximately 15% risk of developing acute myeloid leukemia (AML; called here CN/AML). Most CN/AML patients co-acquireCSF3RandRUNX1mutations, which play cooperative roles in the development of AML. To establish an in vitro model of leukemogenesis, we utilized bone marrow lin−cells from transgenic C57BL/6-d715Csf3rmice expressing a CN patient–mimicking truncatedCSF3Rmutation. We transduced these cells with vectors encodingRUNX1wild type (WT) orRUNX1mutant proteins carrying the R139G or R174L mutations. Cells transduced with theseRUNX1mutants showed diminished in vitro myeloid differentiation and elevated replating capacity, compared with those expressing WTRUNX1. mRNA expression analysis showed that cells transduced with theRUNX1mutants exhibited hyperactivation of inflammatory signaling and innate immunity pathways, including IL-6, TLR, NF-kappaB, IFN, and TREM1 signaling. These data suggest that the expression of mutatedRUNX1in aCSF3R-mutated background may activate the pro-inflammatory cell state and inhibit myeloid differentiation.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (43)
CITATIONS (5)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....